5-Amino-1MQ
Aliases: 5A1MQ
Last verified: 2026-09-23
The short version
A small molecule — inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that "spends" NAD+ and slows fat metabolism. In mice: fat loss without dietary change; a biohacking favorite. Key fact: No controlled human trials exist. Everything known about 5-Amino-1MQ in humans comes from indirect sources and self-reports. Status: research chemical. Not approved; research chemical.
Identity & type
- Molecular type
- mali molekul
- Origin
- A small molecule — inhibitor of NNMT (nicotinamide N-methyltransferase), an enzyme that "spends" NAD+ and slows fat metabolism.
Mechanism of action
NNMT inhibition → increased NAD+/SAM balance → sirtuin activation and increased adipocyte energy expenditure.
not confirmed in humans
Dosing & routes
Official / clinical context
No approved official document exists for 5-Amino-1MQ. Any protocols mentioned are to be read as information, not as a recommendation.
Regulator-approved labeling and published study designs — never a recommendation.
Community-reported practice
Anecdotal 50–150 mg/day orally; or 50–100 mcg SC. The community reports accelerated fat loss (1–2 kg/month without dietary change), more energy and better insulin sensitivity; some feel nothing. Often combined with NAD+ stacks.
Unverified self-reports. Not medical advice. Not endorsement.
Expected effects (community)
The community reports accelerated fat loss (1–2 kg/month without dietary change), more energy and better insulin sensitivity; some feel nothing. Often combined with NAD+ stacks.
Protocol — official vs community
Official / label
No approved product. NNMT inhibitor studied preclinically for metabolic effects.
Duration: Preclinical only.
Small-molecule NNMT inhibition — one of the more interesting recent metabolic research threads.
Community (anecdotal)
50–150 mg oral daily.
- Cycle:
- 4–8 weeks.
- Break:
- 4 weeks.
Cost is the community brake; safety data in humans is essentially anecdote.
Human evidence
No controlled human trials exist. Everything known about 5-Amino-1MQ in humans comes from indirect sources and self-reports.
Preclinical evidence
Preclinical (Univ. of Texas): −30% fat mass in mice on high-fat diet; no human studies.
Known risks
- Unknown in humans; theoretical concerns about chronic NNMT inhibition.characterized
- Unregulated injectable supply — sterility, purity and accurate dose not assuredtheoretical
Teal: characterized in clinical/labeling contexts. Amber: theoretical or reported outside controlled settings.
Unknowns & evidence gaps
- All human pharmacokinetics, safety and efficacy
Frequently asked questions
References
Systematic references are being expanded; verify sources directly before any decision.